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The goal of this trial is to compare two techniques for tensioning retropubic midurethral slings: a Mayo
scissor between the tape and urethra vs. a Babcock clamp creating a measured loop underneath the
urethra. The primary outcome is a composite of abnormal bladder function at 12 months post surgery.
Abnormal bladder function is deﬁned as bothersome stress incontinence or worsening over active
bladder symptoms, a positive cough stress test, re-treatment of stress urinary incontinence, post-
operative urinary retention requiring either catheterization beyond 6 weeks or surgical intervention.
Secondary outcomes include the duration of post operative urinary retention, quality of life scores, and
physical examination. This article describes the rationale and design of this clinical trial, which will be of
interest to those who care for patient with pelvic ﬂoor disorders such as stress urinary incontinence.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 1996, Ulmsten described the tension-free vaginal tape for
stress urinary incontinence (SUI). The technique for placement was
speciﬁed as having the sling “loosely placed e without elevation e
around the urethra”, and it was intended for intra-operative cough
stress testing (CST) to be performed to determine the tension of the
tape [1]. Since that introduction, a number of techniques have been
described as CST can not always be performed in the operating
theatre. Reasons for this include the tape being placed with the
patient under general anesthetic or a deep sedative that does not
allow the patient to follow commands. As such, others have advo-
cated for intra-operative suprapubic pressure (Crede’s maneuver)
[2], the use of an instrument as a spacer between the urethra and
tape [3], and a standardized way of measuring the amount of tape
left in the suburethral space by using a Babcock clamp to create a
loop of free tape [4].
Few studies on how retropubic tapes should be tensioned exist
[5e9]. These papers have mixed results and are limited to evalua-
tion of provocative cough stress testing in the operating room.
Some studies have found that women with intra-operative coughand).
Inc. This is an open access article ustress test did not have different outcomes compared to those who
had the tension of their tapes determined by placement of surgical
scissors as a spacer [5,7]. In contrast, others found superior
improvement in SUI symptoms when an intra-operative cough
stress test was used rather than no provocative testing [6].
Given the minimal body of data on the best practice of intra-
operative retropubic sling tensioning, a well designed trial of two
standardized techniques is required. The impact of such a study
would be far reaching. If a preferred technique could be determined
by such a study, it could facilitate training, thus improving patient
outcomes, decreasing complication rates, and setting a standard
that provides medico-legal reference in the future.2. Materials and methods
2.1. Rationale for tensioning methods used in this protocol
To determine which techniques were currently used by sur-
geons in Canada, an anonymous questionnaire was administered at
an interdisciplinary Female Pelvic Medicine & Reconstructive Sur-
gery (FPMRS) conference in Calgary, Alberta, Canada. This confer-
ence was attended by the majority of FPMRS surgeons in Western
Canada, as well as a small proportion of surgeons from Eastern
Canada. Of the 21 surgeons in attendance, 19 responded that they
routinely performed retropubic midurethral slings. Respondentsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Study design ﬂow diagram.
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tightness of a retropubic midurethral sling?” and given the op-
portunity to provide one or more responses. All answered the
question with one to three answers. The most frequently reported
technique was to place curved Mayo scissors between the sling and
urethra (57.9%, n¼ 11). Other reported techniques included applied
pressure on the bladder by the surgeon, “Crede’s maneuver” (15.8%,
n ¼ 3), “eye balling” or visual inspection of tension without an in-
strument (15.8%, n ¼ 3), the use of a Babcock clamp over a
measured portion of the mesh (10.5%, n ¼ 2), urethroscopy (5.3%,
n ¼ 1), placement of Metzenbaum narrow scissors between the
sling and urethra (5.3%, n ¼ 1), a dilator between the sling and
urethra (5.3%, n¼ 1), a dilator in the urethra (5.3%, n¼ 1), and intra-
operative cough testing (5.3%, n ¼ 1).
In deciding which techniques to compare, it was decided that
one arm of the study should evaluate the most frequently reported
method and the technique used most often by the surgeons
designing the study, use of Mayo scissors as a spacer. In choosing a
second arm of the study, we wanted a highly reproducible tech-
nique that could be standardized between surgeons. Provocative
techniques, such as intra-operative cough tests and Crede’s ma-
neuvers were decided against as level of sedation for coughing, and
force used during Crede’s, can not be standardized between pa-
tients and surgeons. Additionally, provocative measures can not be
performed under general anesthetic (GA). In our experience, a
signiﬁcant portion of women opt for GA during their procedure.
Visual inspection without an instrument was decided against, as
there would be no way to objectively measure the amount of ten-
sion for each case. Dilators were decided against, as there was no
consensus on what size of dilator should be used. While not a
frequently reported technique, the use of a Babcock clamp over a
measured portion of the mesh [4] was felt to be the most repro-
ducible. This is because the distance in the “loop” held by the
Babcock could be measured with a surgical ruler to an exact length
for all cases.
2.2. Study design
We developed a randomized clinical trial (RCT) with superiority
study design to be carried out at two Urogynecology centers in
western Canada (Calgary and Edmonton, Alberta). Outcomes of
retropubic mid urethral slings (Boston Scientiﬁc Advantage Fit)
tensioned by two standardized non-provocative techniques: sur-
gical scissor as a spacer vs. creation of a tape-loop with babcock
clamp [3e5] will be compared. Study ﬂow and design are shown in
Fig. 1.
2.3. Participant selection
2.3.1. Inclusion criteria
Women aged 18 or older who have elected for surgical man-
agement of symptomatic stress urinary incontinence. They must
have the ability to read and write in English for completing
informed consent and quality of life forms. Patient must consent to
participation in the RCT. Prolapse surgery at time of TVT placement
is allowed within the study parameters.
2.3.2. Exclusion criteria
Women who elect for non-surgical management of their
symptomatic stress urinary incontinence, or who decline partici-
pation in this RCT. Those who have had a prior incontinence pro-
cedure, or who have pre-existing urinary retention deﬁned as post-
void residual >100 mL are not eligible. Women who are clinically
felt to have overactive bladder as the predominant cause of their
urinary incontinence are excluded. Women who haveasymptomatic stress urinary incontinence (latent SUI) are not
included, as the lack of symptomsmeans the condition should have
minimal impact on their quality of life and therefore, we would be
unable to detect any positive difference in these parameters as a
result of the surgical procedure.2.4. Recruitment
Women referred to any of the collaborating clinicians, who fulﬁll
the inclusion and exclusion criteria will be offered the opportunity
to join the trial. The woman's clinician will brieﬂy introduce the
study, then the woman will be referred to the study nurse who is
not involved in the woman's routine clinical care. The study nurse
will explain the trial in full and provide detailed information.
Women may have further discussion with their surgeon if they
wish, and women who decide to participate will sign a consent
form. Recruitment began in September 2015. During the ﬁrst 7
months, 99 women enrolled in the study. Using a projected
recruitment rate of 8e10 participants per month, enrollment is
expected to ﬁnish in September 2018.
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No compensation is provided to study participants. Surgical
procedures, including the purchase of the surgical device, hospital
fees and physician payments, are in accordance with the provincial
single payer universal health care system (Alberta Health Care).
2.6. Randomization
Participants will be randomized with equal probability to
tensioning by scissor method or by Babcock method using a
randomization service through the data manager at the University
of Calgary Department of Obstetrics and Gynaecology. Permuted
block randomization with blocks of varying size (1e4) will be
employed. Randomization will be stratiﬁed by surgeon, and pres-
ence or absence of concomitant pelvic organ prolapse surgery.
Randomization a few days prior to surgery will ensure that as many
patients as possible will receive the allocated operation and reduce
the chances that women will withdraw from the study or change
their minds after randomization. Blinding of the surgeonwill not be
possible. Randomization information will be conveyed to the study
surgeon by the principal investigator or the study nurse, by conﬁ-
dential phone call on day of surgery. The patient will remain blin-
ded until the 12 month post operative visit. All post-operative
assessments and examinations will be performed by a research
nurse or physician at each site who did not perform the procedure
and is blinded to treatment assignment.
2.7. Intervention
2.7.1. Scissor spacer
For the scissor spacer technique, curved Mayo scissors will be
inserted in the space between the posterior urethra and plastic
mid-line tab. The scissors will be advanced up to the hinge screw.
The scissors will be kept at a neutral 0 angle parallel to the pa-
tient's posterior urethra. The scissors should not be forced against
the pubic bone, unless they naturally come to lie there. By using the
patient's own anatomy as the reference point, it will ensure the
tape is positioned at the same angle for all participants regardless of
the degree of trendelenburg and hip ﬂexion they have been placed
in. To ensure the scissor is at 0 to the urethra, the surgeon can
inspect from the lateral aspect of the patient to see how theMayo is
in contact with the posterior urethra. To ensure there is no angling
of the scissors, there should be no visible space between the pos-
terior urethra and the hub of the scissor, as this occurs if the scissors
are under traction towards the ﬂoor. There should also be no visible
space between the posterior urethra and the tips of the scissors, as
this occurs if the scissors are under traction towards the operating
room ceiling. The tape will be tensioned so that the midline tab
rests just ﬂush against the screw hinge, without any pressure,
ensuring the scissors are not pulled against the urethra. With the
scissors in place, the tab will be cut and the plastic sheath removed
from the mesh. The scissors will then be removed, the excess mesh
tape trimmed at the suprapubic skin level and incisions closed. A 16
or 18 French foley catheter will placed at the start of the surgical
procedure and will be left in place during these steps.
2.7.2. Babcock clamp
For the Babcock clamp technique, the protective tab will be cut
off ﬁrst and the protective sheath advanced 1 cm off midline on
each side. Next a 1.5 cm of tape length will be measured out with a
sterile surgical ruler (7.5 mm on each side of midline). The tape will
be folded in themidline, and the clamp placed creating a 1.5 loop or
“knuckle”. The tape will then be tensioned by grasping both the
suprapubic ends of the tape and protective sheath with Kellyclamps. The Kelly clamps will be used to pull the tape and sheath
upward through the suprapubic skin incisions so that the Babcock
clamp rests gently against the urethra. At this point, the protective
sheath will be fully removed so the tape cannot be tensioned
further. The Babcock is then released, ensuring exactly 1.5 cm of
tape loose in the suburethral space. A 16 or 18 French foley catheter
will be left in place during these steps [5].
2.8. Data collection, measures and outcomes, safety monitoring
2.8.1. Baseline & study measures
After consenting to join the study, baseline data will be extrac-
ted from the patient's chart including demographics, body mass
index (BMI), parity, estrogen use and hormonal status. Presence or
absence of vaginal atrophy, standardized POP-Q assessment of
pelvic organ prolapse, uroﬂow parameters and post void residual
will be recorded. All women will be asked to complete a ques-
tionnaire including pelvic ﬂoor symptoms and incontinence-
related quality of life (Urinary Distress Inventory UDI-6, Inconti-
nence Impact Questionnaire IIQ-710,11, International Consultation
on Incontinence Modular Questionnaire for Female Lower Urinary
Tract Symptoms e ICIQ-FLUTS [10]). Baseline and repeated study
measures are shown in Fig. 2.
2.8.2. Considerations in the selection of the primary outcome
The primary outcome of the study is presence or absence of
abnormal post-operative bladder function, a composite assessed
at 12 months after surgery and composed of one or more of the
following: 1) signiﬁcantly bothersome SUI or OAB symptoms after
surgery as measured on questions 1, 2, & 3 of the UDI-6, 2) a pos-
itive cough stress test in the ofﬁce, 3) re-treatment for stress uri-
nary incontinence (repeat surgery or pessary use), 4) post-
operative urinary retention (presence of self-catheterization at 6
weeks post-operatively or beyond, or therapeutic intervention for
retention at any time during the 12 months after, such as pelvic
ﬂoor physiotherapy, sling lysis, urethrolysis, or sacral nerve stim-
ulation). This composite outcome was chosen as it gives weight to
suboptimal outcomes such as persistent SUI, de novo overactive
bladder and post-operative urinary retention. Similar outcomes
have been used in the past [12,13], and values from those trials can
be used for sample size calculation.
2.8.3. Secondary outcome measures
The secondary outcomes of the study include: 1) rates of
discharge from hospital with on-going need for catheterization, 2)
duration of self catheterization after surgery in days, 3) standard-
ized questionnaire scores (UDI-6 & IIQ-7, ICIQ-FLUTS), 4) stan-
dardized 1-h pad test values in grams of urine lost, 5) urine ﬂow
test parameters at 12 months, such as peak ﬂow rate in milliliters/
second and post-void residual in milliliters 6) new prescription of a
medication to treat over-active bladder symptoms, determined by
chart review 7) vaginal examination at 12 months (normal vs.
abnormal palpation, and type of abnormality such as mesh erosion
or tenderness during palpation).
2.8.4. Safety monitoring
At the midpoint of study enrollment (n ¼ 159), an interim
analysis of urinary retention rates at or beyond 6 weeks is planned.
This safety endpoint has been chosen, as obstructed voiding is the
outcome which has the greatest capacity for harm. A retention rate
of 4.7% at 6 weeks is expected in the Mayo scissor group [13]. At
mid-point enrollment, the study will be powered to detect a 4-fold
increase in short term retention. In this event the study would be
halted, as an increase of that magnitude would be too large for
investigators to feel comfortable continuing.
Baseline Data CollecƟon
Demographics: age, BMI, 
smoking status, parity, 
menopausal status, hormone 
use
QuesƟonnaires: ISI, Presence 
of SUI & UUI symptoms in 
preceding 7 days, UDI-6, IIQ-7, 
ICIQ-FLUTS
Peri-operaƟve Data 
CollecƟon
AnestheƟc agent
Length of surgery
ComplicaƟons
Voiding protocol aŌer surgery
6 week post-op vaginal exam
6 week post-op Uroflow
12-Month Data CollecƟon
Demographics: age, BMI
QuesƟonnaires: ISI, Presence 
of SUI & UUI symptoms in 
preceding 7 days, UDI-6, IIQ-7, 
ICIQ-FLUTS, saƟsfacƟon with 
surgery
12 month physical exam: 
cough stress test, erosion 
check, examinaƟon for pelvic 
pain, 1-hour pad test
Chart check: post-operaƟve 
urinary retenƟon, retreatment 
for SUI symptoms, prescripƟon 
for OAB symptoms 
Fig. 2. Study measured along protocol timeline.
E.A. Brennand, S. Kim-Fine / Contemporary Clinical Trials Communications 3 (2016) 60e64 632.9. Statistical analysis
Descriptive statistics (mean, standard deviation, median, inter-
quartile range, proportions) will be calculated for baseline data.
Baseline patient characteristics of age, ethnicity, nulliparity,
smoking, menopausal status, presence of UUI symptoms before
surgery and quality of life scores will examined to determine
whether there are any major imbalances between the two treat-
ment groups that would need to be adjusted for in the analysis of
the primary or secondary outcomes.
Outcomes will be analyzed according to original treatment
assignment (intent to treat). The primary analysis will compare the
proportion of women with abnormal bladder function in each
group (scissor method vs Babcock method) using the chi-square
test. Differences in proportion will be presented along with 95%
conﬁdence intervals (CI).
Categorical secondary outcomeswill be compared using the chi-
square test or Fisher's exact test. Estimates for differences in pro-
portions and 95% CI will be reported. Individual components of the
composite primary outcome will be explored using the chi-square
or Fisher's exact test. Continuous outcomes such as QoL scores
will be compared using the student's t-test if normally distributed,
or Mann-Whitney U test if not normally distributed.
Secondary analyses are planned to evaluate whether factors
such as obesity, age, and pre-operative severity of incontinence (ISI)
are risk factors for surgical failure. These analyses will include chi-
square tests and t-tests, as appropriate, as well as logistic regression
modelling.
This data will be managed in Microsoft Access with analysis
carried out using SAS.
2.10. Sample size justiﬁcation
Assuming a rate of 5.3% for bothersome post-operative SUI, and
6.3% for bothersome post-operative UUI [11], a conservative sur-
gical revision rate for urinary retention of 1.1% [13], and a retention
rate of 4.7% at  6 weeks post-operative [13], the additive value of
our primary outcome is 17.4%. Acknowledging overlap within the
groups (such as the likelihood that all womenwith surgical revision
will fall into the retention group) we assume an overall rate of our
primary outcome, abnormal post-operative bladder function, in
the range of 15e16%. In a superiority trial study design, 276 patients
(n ¼ 138 each group) are required to have 80% power to detect a
10% difference in our primary outcome with a 90% two-sided
conﬁdence interval (alpha ¼ 0.05). The 10% difference was chosen
as our group determined this degree of improvement would be
required in order for our practice to change in favor of the morecomplex Babcock method. Assuming a loss to follow-up rate of 15%
based on a different midurethral sling trial conducted by our group
[11], the total enrollment goal is 318 women.
3. Discussion
3.1. Study design challenges and limitations
The MUST trial is innovative and aims to characterize how two
approaches on the tensioning of a retropubic sling affect the pro-
cedure's outcome. To our knowledge, this has not been done before.
The survey performed as part of trial development conﬁrmed
our suspicion that use of the Mayo Scissor is the most common
method of tensioning a retropubic sling in Western Canada. The
choice of comparison technique was challenging, as results showed
no clear second favorite. Wewanted the comparator to be a precise,
standardized and reproduciblemethodwhich could be described in
detail for readers. The Babcock technique was chosen as it met
those requirements.
The next challenge was engaging surgeons in the study, which
requires them to deviate from their usual tensioning practice for
half of surgical cases. Six surgeons were approached to take part in
the trial after the protocol was ﬁnalized. Five agreed to take part;
the individual who declined indicated they did not feel comfortable
deviating from their usual practice.
One of the limitations of the study protocol is that wewill not be
performing a baseline pad test upon enrollment into the study. This
means we can not objectively quantify the severity of leakage prior
to surgery. Although this has not commonly been done in other
studies of the TVT, the study authors desired to quantify the
severity of leakage of each participant. If the severity of leakage is
characterized, we can explore if the two techniques perform
differently for women with mild or severe leakage. While we
considered including an enrollment pad test, we ultimately chose
not to based on our experiences with a previous clinical trial at our
institution [11]. Experience from that trial gave us the impression
that patients ﬁnd pad-testing cumbersome, and so it was felt that
use of pad testing at enrollment would be a barrier to participation
due to additional upfront time requirements by patients. Instead
we chose to use the Incontinence Severity Index [14] to qualify the
severity of leakage experienced before and after surgery.
3.2. Strengths
The ﬁve participating surgeons represent two different Urgy-
necology departments in the province of Alberta. The large multi-
site design is a strength, as it makes our study generalizable to
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pating surgeon, or a single site, it would difﬁcult to say if outcomes
reﬂected the two techniques or if the outcomes were inﬂuenced by
regional practices or surgical expertise. By including surgeons with
varied backgrounds, we can more conﬁdently say the results are
inﬂuenced mainly by the two techniques under study.
Another strength of this study is that we are looking at the
impact of the two techniques on both patient centered subjective
outcomes, as well as objective outcomes. It also characterizes the
complications of surgery such as rates and duration of urinary
retention, the need for post operative therapy for over-active
bladder symptoms, as well as mesh erosion and vaginal pain. A
detailed study of retropubic sling complications is valuable, given
the recent increase in litigation involving mesh for prolapse and
incontinence. Our trial follows these complications in the short
term (ﬁrst six weeks), as well as longer follow up to the 1 yearmark.
We believe there will be broad interest in this study from gy-
necologists and urologists, as the data will give them the option to
standardize practice. This study will be of particular interest to
those who teach retropubic sling procedures, as the evaluation of
the two techniques will allow educators to provide evidence-based
instruction on the pros and cons of options for sling tensioning.
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